SG3 Management’s Forte Biosciences FBRX Stock Holding History

SG3 Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-416	Closed	-$31K	–	1118
2021 Q3	$31K	Buy	+416	New	+$230K	﹤0.01%	932

Other funds holding FBRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG3 Management's FBRX Position: Q4 2021 in Review

SG3 Management sold out of Forte Biosciences (FBRX) in Q4 2021, closing a stake of 200 shares — an estimated $15K sold.

SG3 Management first reported a position in FBRX in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 52 funds tracked by Wall St. Rank hold FBRX as of Q4 2021.

SG3 Management reported no remaining Forte Biosciences position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 200 Forte Biosciences shares in Q4 2021, an estimated $15K.
SG3 Management first reported a position in Forte Biosciences in Q3 2021 and held it in 1 quarter.
SG3 Management's Forte Biosciences position peaked at $15K in Q3 2021.
52 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.